- Advertisement -

Medovex’s Transition to H-CYTE Underscores Biotechnology Focus – GlobeNewswire

ALPHARETTA, Ga., June 24, 2019 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB: Symbol MDVX) ("Medovex" or the "Company"), is transitioning to its new name H-CYTE...

Applying an evolutionary perspective to medicine can spark biomedical innovations

The word 'evolution' may bring to mind dusty dinosaur bones, but it impacts our health every day. For example, even though antibiotics were invented...

Suspended sediment reduced by rapid revegetation after Fukushima decontamination

Researchers from the University of Tsukuba find that soil decontamination efforts in Fukushima result in constant, high levels of suspended sediments and a rapid...

Insilico Medicine discovers novel preclinical candidate to address idiopathic pulmonary fibrosis

Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ("AI") and drug discovery -- linking together generative chemistry and biology for the first time...

Simple blood tests can benefit women with breast cancer

Reviewed by Emily Henderson, B.Sc.Sep 11 2020 A blood test that can identify a variety of mutations in advanced breast cancer can reliably match women...

BMS Selling Celgene’s Otezla to Address FTC “Concerns” on $74B Deal

Otezla® (apremilast) Bristol-Myers Squibb (BMS) plans to divest itself of the psoriasis drug Otezla® (apremilast) as part of its planned $74 billion acquisition of Celgene,...

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionized the treatment of type 2 diabetes (T2D). None of these blockbuster...

ADC Developmentfrom Concept to Clinic

Read Now Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery...

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionized the treatment of type 2 diabetes (T2D). None of these blockbuster...

ADC Developmentfrom Concept to Clinic

Read Now Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery...

Designing the Ecosystem for CGT Success

Read Now Preserving the Promise: Insights from The Cell Summit ’26 In July 2026, BioLife Solutions welcomed leaders from across the cell...

more new items

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionized the treatment of type 2 diabetes (T2D). None of these blockbuster...

ADC Developmentfrom Concept to Clinic

Read Now Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery...

Designing the Ecosystem for CGT Success

Read Now Preserving the Promise: Insights from The Cell Summit ’26 In July 2026, BioLife Solutions welcomed leaders from across the cell...